Tivic CEO To Present at Emerging Growth Virtual Conference

Presentation will cover recent milestones including NIAID agreement for Entolimod study

Mar. 30, 2026 at 7:25am

Got story updates? Submit your updates here. ›

A high-end, photorealistic studio still-life featuring a collection of polished medical instruments, vials, and laboratory equipment arranged elegantly on a clean, monochromatic background, symbolizing Tivic's work in developing innovative immunotherapeutics.Tivic's agreement with NIAID to study its lead drug candidate Entolimod represents a key milestone in the company's efforts to advance innovative immunotherapies.San Antonio Today

Tivic Health Systems, Inc., a clinical-stage immunotherapeutics company, announced that its newly appointed CEO Michael K Handley will deliver a corporate update at the Emerging Growth Virtual Conference taking place April 1-2, 2026. Handley will highlight key milestones, including the company's recent agreement with the National Institute of Allergy and Infectious Diseases (NIAID) to sponsor and conduct a preclinical study evaluating Entolimod for gastrointestinal acute radiation syndrome.

Why it matters

Tivic's lead candidate Entolimod has received Fast Track and Orphan Drug designations from the FDA for the treatment of acute radiation syndrome. The NIAID agreement represents an important milestone for the company as it advances Entolimod through the development pipeline.

The details

Under the NIAID agreement, the agency will sponsor and conduct a preclinical study evaluating Entolimod for gastrointestinal acute radiation syndrome (GI-ARS). If the data from this study demonstrates efficacy, NIAID may support future studies for the GI-ARS condition using Entolimod.

  • Tivic CEO Michael K Handley will present at the Emerging Growth Virtual Conference on April 1, 2026 from 2:55-3:05 PM Eastern Time.
  • The Emerging Growth Virtual Conference is taking place on April 1-2, 2026.

The players

Tivic Health Systems, Inc.

A clinical-stage immunotherapeutics company developing biologics that activate innate immune pathways, including the lead candidate Entolimod for acute radiation syndrome.

Michael K Handley

The newly appointed Chief Executive Officer of Tivic Health Systems, Inc.

National Institute of Allergy and Infectious Diseases (NIAID)

Part of the National Institutes of Health, NIAID will sponsor and conduct a preclinical study evaluating Tivic's Entolimod for gastrointestinal acute radiation syndrome.

Got photos? Submit your photos here. ›

What’s next

If the preclinical study with NIAID demonstrates efficacy of Entolimod for GI-ARS, the agency may support future clinical trials of the drug for this indication.

The takeaway

Tivic's agreement with NIAID represents an important milestone as the company advances its lead candidate Entolimod, which has received Fast Track and Orphan Drug designations from the FDA for acute radiation syndrome.